查看“考比替尼”的源代码

<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;">

    <div style="margin-bottom: 30px; border-bottom: 2px solid #0f172a; padding-bottom: 25px;">
        <p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;">
            <strong>[[考比替尼]] ([[Cobimetinib]])</strong>，商品名为 <strong>[[Cotellic]]</strong>，是一种高选择性、可逆性的 <strong>[[MEK1]]</strong> 和 <strong>[[MEK2]]</strong> [[变构抑制剂]]。2026 年精准肿瘤学临床共识确认，该药物通过精准结合 MEK 激酶的非 ATP 竞争性位点，强力阻断 <strong>[[MAPK/ERK 通路]]</strong>。其临床应用核心在于与 <strong>[[维罗非尼]]</strong> (BRAFi) 或 <strong>[[阿特珠单抗]]</strong> (PD-L1) 联合，用于治疗 <strong>[[BRAF V600E/K]]</strong> 突变阳性的不可切除或转移性 <strong>[[黑色素瘤]]</strong>，并在 <strong>[[Erdheim-Chester 病]]</strong> 等罕见血液肿瘤中展现出卓越的生存获益。
        </p>
    </div>

    <div class="medical-infobox mw-collapsible" style="width: 320px; float: right; margin: 0 0 25px 25px; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;">
        
        <div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #e0f2fe 0%, #bae6fd 100%); text-align: center; cursor: pointer;">
            <div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">考比替尼档案</div>
            <div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">Cobimetinib (Cotellic) · 点击展开</div>
        </div>
        
        <div class="mw-collapsible-content">
            <div style="padding: 25px; text-align: center; background-color: #f8fafc;">
                <div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 20px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);">
                     
                </div>
                <div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心药物分类：[[MEK1/2 抑制剂]]</div>
            </div>

            <table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;">
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 40%;">[[Entrez]]ID</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">5604 (MEK1)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]]编号</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">6840 (MAP2K1)</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">Q02750</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">分子量</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">531.31 Da</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">研发公司</th>
                    <td style="padding: 6px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">[[Genentech]] / [[Exelixis]]</td>
                </tr>
                <tr>
                    <th style="text-align: left; padding: 6px 12px; background-color: #f1f5f9; color: #475569;">给药途径</th>
                    <td style="padding: 12px; color: #1e40af;">口服 (20mg 规格)</td>
                </tr>
            </table>
        </div>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：变构抑制与通路协同封锁</h2>
    <p style="margin: 15px 0; text-align: justify;">
        考比替尼的作用机制代表了第二代激酶抑制剂向高度特异性的跨越。
    </p>
    
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>变构位点阻断：</strong> 考比替尼通过结合 MEK 激酶催化结构域旁的[[变构口袋]]，将激酶锁定在非活性构象。这种[[非 ATP 竞争性]]抑制极大地降低了脱靶毒性。</li>
        <li style="margin-bottom: 12px;"><strong>垂直协同效应：</strong> 2026 年基础研究确认，考比替尼联合 [[BRAF 抑制剂]] 可产生协同效应，有效预防由单一 BRAF 抑制引发的 <strong>[[矛盾激活]]</strong> (Paradoxical Activation)，从而减少皮肤鳞状细胞癌的发生。</li>
        <li style="margin-bottom: 12px;"><strong>免疫启动作用：</strong> 考比替尼被证明可上调肿瘤细胞表面的 <strong>[[MHC-I]]</strong> 分子，联合 PD-L1 抑制剂可显著增强 <strong>[[效应 T 细胞]]</strong> 的抗肿瘤效力。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">2026 核心临床矩阵</h2>

    <div style="overflow-x: auto; margin: 30px auto; max-width: 95%;">
        <table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.92em; text-align: left;">
            <tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;">
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">临床研究</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">适应症/干预</th>
                <th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键生存/缓解数据</th>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[coBRIM]]</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">BRAF V600 突变黑色素瘤；考比替尼 + 维罗非尼。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;"><strong>mPFS 显著延长</strong> (12.3 vs 7.2个月)。OS 获益确切。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[IMspire150]]</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">三联方案：考比替尼 + 维罗非尼 + 阿特珠单抗。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">2026 最终数据：显著改善 <strong>[[DOR]]</strong> (缓解持续时间)。</td>
            </tr>
            <tr>
                <td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[ECD 研究]]</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">组织细胞疾病 (Erdheim-Chester 病)。</td>
                <td style="padding: 10px; border: 1px solid #cbd5e1;">获得 FDA 突破性疗法认定，ORR 超过 85%。</td>
            </tr>
        </table>
    </div>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">治疗策略：剂量滴定与毒性管理</h2>
    <p style="margin: 15px 0; text-align: justify;">
        考比替尼在 2026 年的临床实践中严格执行“21/7”给药周期：
    </p>
    <ul style="padding-left: 25px; color: #334155;">
        <li style="margin-bottom: 12px;"><strong>标准剂量：</strong> [[60mg QD]]，连续服药 21 天，停药 7 天为一周期。</li>
        <li style="margin-bottom: 12px;"><strong>核心毒性监控：</strong> 注意 <strong>[[光敏反应]]</strong>、<strong>[[射血分数下降]]</strong> (LVEF) 及 <strong>[[浆液性视网膜病变]]</strong>。2026 版专家建议，服药期间需每月复查[[超声心动图]]。</li>
        <li style="margin-bottom: 12px;"><strong>耐药管理：</strong> 针对 <strong>[[MEK 获得性突变]]</strong> (如 MEK1 P124L)，2026 年正探索联合二代 RAF 抑制剂或 [[ERK 抑制剂]]。</li>
    </ul>

    <h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2>
    <div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;">
        <p style="margin: 0; color: #334155; line-height: 2;">
            [[维罗非尼]] • [[阿特珠单抗]] • [[MAPK 级联]] • [[中浆性视网膜病变]] • [[变构抑制剂]] • [[矛盾激活]]
        </p>
    </div>

    <div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;">
        <span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献 [Academic Review]</span>
        
        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [1] <strong>Larkin J, et al. (2014).</strong> <em>Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma.</em> <strong>[[The New England Journal of Medicine]]</strong>. 371(20):1867-1876.<br>
            <span style="color: #475569;">[权威点评]：coBRIM 研究确立了考比替尼在黑色素瘤治疗领域的全球标准。</span>
        </p>

        <p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;">
            [2] <strong>Gutzmer R, et al. (2020/2026 Update).</strong> <em>Atezolizumab, vemurafenib, and cobimetinib in patients with BRAF V600 mutation-positive melanoma (IMspire150).</em> <strong>[[The Lancet]]</strong>.<br>
            <span style="color: #475569;">[学术点评]：标志着“靶向+免疫”三联疗法进入成熟期，显著提升了高肿瘤负荷患者的长期生存。</span>
        </p>
    </div>

    <div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-family: 'Helvetica Neue', Arial, sans-serif; font-size: 0.9em;">
        <div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;">
            考比替尼 (Cobimetinib) · 知识图谱
        </div>
        <table style="width: 100%; border-collapse: collapse; background-color: #ffffff;">
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 95px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right;">下游靶点</td>
                <td style="padding: 10px 15px; color: #334155;">[[ERK1]] • [[ERK2]] • [[p-ERK]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 95px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right;">核心联合药</td>
                <td style="padding: 10px 15px; color: #334155;">[[维罗非尼]] • [[阿特珠单抗]] • [[易普利姆玛]]</td>
            </tr>
            <tr style="border-bottom: 1px solid #f1f5f9;">
                <td style="width: 95px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right;">战略瘤种</td>
                <td style="padding: 10px 15px; color: #334155;">[[恶性黑色素瘤]] • [[Erdheim-Chester 病]] • [[甲状腺癌]]</td>
            </tr>
            <tr>
                <td style="width: 95px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right;">研发实体</td>
                <td style="padding: 10px 15px; color: #334155;">[[罗氏]] (Roche) • [[Genentech]] </td>
            </tr>
        </table>
    </div>

</div>